The role of Aflibercept in the management of age-related macular degeneration

References

• Klein R, Peto T, Bird A, et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004 Mar;137(3):486–495. doi:10.1016/j.ajo.2003.11.069.
   PubMed Web of Science ®Google Scholar
• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106e116. doi:10.1016/S2214-109X(13)70145-1.
   Web of Science ®Google Scholar
• Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004 Apr;122(4):564–572. doi:10.1001/archopht.122.4.564.
   PubMed Web of Science ®Google Scholar
• Prevalence of age-related macular degeneration in the United States. [cited 2015 Oct 2]. Available from: http://www.who.int/blindness/causes/priority/en/index8.html
   Google Scholar
• Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984 Nov;102(11):1640–1642.
   PubMed Web of Science ®Google Scholar
• Verteporfin In Photodynamic Therapy Study G. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization–verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001 May;131(5):541–560.
   PubMed Web of Science ®Google Scholar
• Bressler NM. Treatment of age-related macular degeneration with photodynamic therapy study G. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001 Feb;119(2):198–207.
   PubMed Web of Science ®Google Scholar
• Miller JW. Age-related macular degeneration revisited–piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol. 2013 Jan;155(1):135e13. doi:10.1016/j.ajo.2012.10.018.
   Web of Science ®Google Scholar
• McKibbin M, Devonport H, Gale R, et al. AFLibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. Eye. 2015 Jul;29(Suppl 1):S1–S11. doi:10.1038/eye.2015.77.
   PubMed Web of Science ®Google Scholar
• Veikkola T, Karkkainen M, Claesson-Welsh L, et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000 Jan 15;60(2):203–212.
   PubMed Web of Science ®Google Scholar
• Lee SH, Jeong D, Han Y-S, et al. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res. 2015 Jul;89(1):1–8. doi:10.4174/astr.2015.89.1.1.
   PubMed Web of Science ®Google Scholar
• Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003 Jul;44(7):3186–3193. doi:10.1167/iovs.02-1092.
   PubMed Web of Science ®Google Scholar
• Huo X, Li Y, Jiang Y, et al. Inhibition of ocular neovascularization by co-inhibition of VEGF-A and PLGF. Cell Physiol Biochem. 2015;35(5):1787–1796. doi:10.1159/000373990.
   PubMed Web of Science ®Google Scholar
• Al-Halafi AM. Vascular endothelial growth factor trap-eye and trap technology: AFLibercept from bench to bedside. Oman J Ophthalmol. 2014 Sep;7(3):112–115. doi:10.4103/0974-620X.142591.
   PubMedGoogle Scholar
• Miller JW, Le Couter J, Strauss EC, et al. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013 Jan;120(1):106–114. doi:10.1016/j.ophtha.2012.07.038.
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012 Jun;15(2):171–185. doi:10.1007/s10456-011-9249-6.
   PubMed Web of Science ®Google Scholar
• Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina. 2011 Oct;31(9):1877–1884. doi:10.1097/IAE.0b013e318217373c.
   PubMed Web of Science ®Google Scholar
• Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012 Oct;154(4):682686.e2. doi:10.1016/j.ajo.2012.03.047.
   PubMed Web of Science ®Google Scholar
• Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of AFLibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmology. 2013;7:495–501. doi:10.2147/OPTH.S29974.
   PubMedGoogle Scholar
• Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008 May;92(5):667–668. doi:10.1136/bjo.2007.134874.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10457–10461.
   PubMed Web of Science ®Google Scholar
• Cao J, Zhao L, Li Y, et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. Invest Ophthalmol Vis Sci. 2010 Nov;51(11):6009–6017. doi:10.1167/iovs.09-4956.
   PubMed Web of Science ®Google Scholar
• Saishin Y, Takahashi K, Lima E Silva R, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003 May;195(2):241–248. doi:10.1002/jcp.10246.
   PubMed Web of Science ®Google Scholar
• Nork TM, Dubielzig RR, Christian BJ, et al. Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates. Arch Ophthalmol. 2011 Aug;129(8):1042–1052. doi:10.1001/archophthalmol.2011.210.
   PubMed Web of Science ®Google Scholar
• Oliveira HB, Sakimoto T, Javier JAD, et al. VEGF Trap(R1R2) suppresses experimental corneal angiogenesis. Eur J Ophthalmol. 2010 JanFeb;20(1):48–54.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006 Sep;113(9):1522e122 e14. doi:10.1016/j.ophtha.2006.05.055.
   Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009 Nov;116(11):21418e1.
   Google Scholar
• Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology. 2011 Jun;118(6):1098–1106. doi:10.1016/j.ophtha.2011.03.020.
   PubMed Web of Science ®Google Scholar
• Brown DM, Heier JS, Ciulla T, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology. 2011 Jun;118(6):1089–1097. doi:10.1016/j.ophtha.2011.02.039.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 study groups. Intravitreal AFLibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537–2548.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal AFLibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014 Jan;121(1):193–201. doi:10.1016/j.ophtha.2013.08.011.
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009 Jan;116(1):5765e5.
   Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419–1431.
   PubMed Web of Science ®Google Scholar
• Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897–1908.
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013 Oct 12;382(9900):1258–1267.
   PubMed Web of Science ®Google Scholar
• Efficacy of Ranibizumab Prn Treatment Compared to AFLibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD (SALT), NCT01958918. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01958918
   Google Scholar
• Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal AFLibercept Injection) (RE-VIEW), NCT01722045. Available from: https://clinicaltrials.gov/ct2/show/NCT01722045
   Google Scholar
• VITAL - Individualising Therapy for Neovascular AMD With AFLibercept, NCT02441816. Available from: https://clinicaltrials.gov/ct2/show/NCT02441816
   Google Scholar
• A Pharmacokinetic Study of Intravitreal AFLibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW), NCT02204683. Available from: https://clinicaltrials.gov/ct2/show/NCT02204683
   Google Scholar
• A Comparison of Ranibizumab and AFLibercept for the Development of Geographic Atrophy in (Wet) AMD Patients (RIVAL), NCT02130024. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02130024
   Google Scholar
• Real Life of AFLibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD (TITAN), NCT02321241. Available from: https://clinicaltrials.gov/ct2/show/NCT02321241
   Google Scholar
• Intravitreal AFLibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Monthly Ranibizumab Injections (SHIFT-2), NCT02002377. Available from: https://clinicaltrials.gov/ct2/show/NCT02002377
   Google Scholar
• Study of Intravitreal REGN2176-3 in Patients With Neovascular (“Wet”) Age-Related Macular Degeneration (AMD) (CAPELLA), NCT02418754. Available from: https://clinicaltrials.gov/ct2/show/NCT02418754?term=REGN2176-3&rank=1
   Google Scholar
• Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (“Wet”) Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME), NCT01997164. Available from: https://clinicaltrials.gov/ct2/show/NCT01997164?term=R910-3-OD-1403&rank=1
   Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul;119(7):1388–1398. doi:10.1016/j.ophtha.2012.03.053.
   PubMed Web of Science ®Google Scholar
• Chang AA, Li H, Broadhead GK, et al. Intravitreal AFLibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology. 2014 Jan;121(1):188–192. doi:10.1016/j.ophtha.2013.08.035.
   PubMed Web of Science ®Google Scholar
• Singh RP, Srivastava SK, Ehlers JP, et al. A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal AFLibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis.AFL. Clin Ophthalmology. 2015;9:1759–1766. doi:10.2147/OPTH.S87043.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Brown DM, Maldonado ME, et al. AFLibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014 Jul;98(7):951–955.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Brown DM, Croft DE, et al. Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. Ophthalmology. 2013 Sep;120(9):19456.e1. doi:10.1016/j.ophtha.2013.06.030.
   PubMed Web of Science ®Google Scholar
• Brown DM, Chen E, Mariani A, et al. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology. 2013 Feb;120(2):349–354. doi:10.1016/j.ophtha.2012.08.008.
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Oishi A, Tsujikawa A, et al. Effects of AFLibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie. 2015 Sep;253(9):1471–1477.
   Google Scholar
• Grewal DS, Gill MK, Sarezky D, et al. Visual and anatomical outcomes following intravitreal AFLibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye. 2014 Jul;28(7):895–899. doi:10.1038/eye.2014.101.
   PubMed Web of Science ®Google Scholar
• Sarao V, Parravano M, Veritti D, et al. Intravitreal AFLibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapy. Retina. 2015 Sep 21:1. doi:10.1097/IAE.0000000000000751.
   Web of Science ®Google Scholar
• Bhavsar KV, Freund KB. Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid. Saudi J Ophthalmol. 2014 Apr;28(2):129–133. doi:10.1016/j.sjopt.2014.03.001.
   PubMedGoogle Scholar
• Semeraro F, Morescalchi F, Duse S, et al. AFLibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther. 2013;7:711–722. doi:10.2147/DDDT.S40215.
   PubMed Web of Science ®Google Scholar
• Elshout M, Van Der Reis MI, Webers CA, et al. The cost-utility of AFLibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie. 2014 Dec;252(12):1911–1920.
   Google Scholar
• Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015 May;159(5):91524e2.
   Web of Science ®Google Scholar
• Grunwald JE, Pistilli M, Ying G-S, et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015 Apr;122(4):809–816. doi:10.1016/j.ophtha.2014.11.007.
   PubMed Web of Science ®Google Scholar